ARV Therapies and Therapeutic Strategies

2015_CROI_Theme_Poster_Banner_v5

2015_CROI_Theme_Poster_Button_v1

About the Program

Program Overview

ARV Therapies and Therapeutic Strategies is a comprehensive, expert review of the 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). This CME program consists of four components: (1) a live and on-demand 1.5 hour Internet symposium that features an overview and discussion of key presentations, selected by the expert faculty discussants; (2) an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) a brief podcast review of key findings from the meeting; and (4) case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The "Comprehensive Expert Review and Discussion of Key Presentations" part of the program will feature HIV experts reviewing and discussing the most important studies on antiretroviral therapy presented at CROI 2015. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from CROI and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This activity will enable all participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program may be accessed at www.viraled.com. 

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2015 and it is not sanctioned by the conference organizers of CROI 2015.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at CROI 2015

  •  Employ the current treatment paradigms for HIV/AIDS, including those supported by studies and data presented at CROI 2015 to improve patient care

  •  Discuss with patients and colleagues the studies and data on newer therapies for HIV/AIDS presented at CROI 2015 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: March 9, 2015

Expiration Date: March 9, 2016

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top

Faculty

José Arribas, MD 
Research Director
(AIDS and Infectious Diseases)
Hospital de La Paz
Madrid, Spain

Ian Frank, MD  
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom

Jürgen Rockstroh, MD
Professor, University of Bonn
Bonn, Germany

Paul Sax, MD 
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Back to Top

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Dr. Jose Arribas:

  • Consulting Fees: Gilead; Janssen; Vertex
  • Fees for Non-CME Services: Gilead; BMS; Merck; Janssen; Vertex
  • Contracted Research: Gilead; GSK; Janssen; Vertex; Salix; Sangamo

Dr. Ian Frank::

  • Consulting Fees: Gilead; ViiV
  • Contracted Research: GS; Bavarian Nordic
  • Other (expert testimony): Janssen

Dr. Graeme Moyle:

  • Consulting Fees: Abbott; Gilead
  • Contracted Research: BMS; Abbott

Dr. Juergen Rockstroh:

  • Consulting Fees: Gilead; Janssen; Bristol-Myers Squibb
  • Contacted Research: Bristol-Myers Squibb; Pfizer; Gilead; VIRxSyS; GSK

Dr. Paul Sax:

  • Consulting Fees: Gilead; Janssen; Bristol-Myers Squibb
  • Contacted Research: Bristol-Myers Squibb; Pfizer; Gilead; VIRxSyS; GSK

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing

2015_CROI_button_113LB_v3 Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial
HIV-1 Therapy Combined Primary Results of Studies GS-US-292-0104 and GS-US-292-0111
2015_CROI_button_143LB_795_v2 Renal and Bone Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate Combined Safety Results of Studies GS-US-292-0104 and GS-US-292-0111
2015_CROI_button_554LB_v2. Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy: LATTE W96 Results
2015_CROI_button_152LB_147_v2 Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV
and HIV-1 (ION-4)

2015_CROI_button_151LB_v2 Daclatasvir in Combination with Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study
2015_CROI_button_748_749LB_v2 Incidence and Risk of Myocardial Infarction by Type in the NA-ACCORD
2015_CROI_button_137_v2 Rosuvastatin Arrests Progression of Carotid Intima-Media Thickness in Treated HIV
2015_CROI_button_23LB_22LB_v2 On Demand PrEP with Oral TDF/FTC in MSM Results of the ANRS Ipergay Trial

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.   

Back to Top

PIM_small

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.


Prepare to print

Share this page:

Get link code to this page     


Back to Top